PFCS
RARE icon

Pale Fire Capital SE’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pale Fire Capital SE’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$551K Hold
16,514
– – 0.04% 43
2026
Q1 		$346K Buy
16,514
+6,303
+62% +$142K 0.03% 43
2025
Q4 		$235K Buy
+10,211
New +$336K 0.02% 45
2025
Q3 		– Sell
-5,600
Closed -$204K – 67
2025
Q2 		$204K Buy
+5,600
New +$202K 0.02% 48

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Pale Fire Capital SE's RARE Position: Q2 2026 in Review

Pale Fire Capital SE held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2026 at 16,514 shares worth $551K. The position accounts for 0.04% of the portfolio, ranked #43.

Pale Fire Capital SE first reported a position in RARE in Q2 2025 and has held it in 4 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Pale Fire Capital SE held 16,514 shares of Ultragenyx Pharmaceutical worth $551K as of Q2 2026.
  • Pale Fire Capital SE left its Ultragenyx Pharmaceutical share count unchanged in Q2 2026.
  • Ultragenyx Pharmaceutical made up 0.04% of Pale Fire Capital SE's portfolio in Q2 2026, its #43 holding.
  • Pale Fire Capital SE first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and has held it in 4 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Pale Fire Capital SE's 13F filing for Q2 2026, filed 13 Aug 2026.